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WILLINGNESS TO PAY PER QUALITY ADJUSTED LIFE-YEAR: IS ONE 
THRESHOLD APPLICABLE FOR ALL DECISION-MAKING?
Zhao FL1, Yue M2, Yang H3, Wang T3, Wu JH2, Li SC1
1University of Newcastle, Callaghan, NSW, Australia; 2306 Hospital of PLA, Beijing, China; 
3The First People’s Hospital of Yunnan Province, Kunming, Yunnan, China
OBJECTIVES: To estimate the Willingness to pay (WTP) per quality-adjusted life-year 
(QALY) ratio with the stated preference data and compare the results obtained 
between chronic prostatits (CP) patients and general population. METHODS: CP 
patients were recruited from two tertiary referral hospitals and the general populations 
were randomly approached in China at the beginning of 2009. WTP per QALY was 
calculated with a formula combining the subjects’ own health-related utility and the 
WTP value. Two widely used preference-based health-related quality of life instru-
ments, EQ-5D and SF-6D, were used to elicit utility for participants’ own health. The 
monthly WTP values for moving from participants’ current health to a perfect health 
described by “11111” status of EQ-5D were elicited using closed-ended iterative 
bidding contingent valuation method. RESULTS: A total of 268 CP patients and 364 
participants from general population completed the questionnaire. We obtained four 
WTP/QALY ratios ranging from $4700 to $7400, which were lower than the pro-
posed thresholds and published researches eliciting the preference for avoiding the risk 
of death. In addition, the WTP/QALY ratios from the general population were signiﬁ -
cantly lower than those from the CP patients and different determinants were associ-
ated with the within group variation identiﬁ ed by multiple linear regression. 
CONCLUSIONS: Preference elicitation methods are acceptable and feasible in the 
socio-cultural context of an Asian environment and the calculation of WTP/QALY 
produced meaningful answers. The lower WTP/QALY elicited than published values 
and higher value from CP patients compared with the general population highlight 
the necessity of considering disease speciﬁ c QALY in estimating WTP/QALY. Our 
results inferred that one threshold might not be enough to serve all decision-making 
under different situations. Further studies using the same methods to conﬁ rm whether 
the WTP/QALY value would be dissimilar among diseases with different impact on 
QoL would be needed. 
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PROBABILISTIC SENSITIVITY ANALYSIS—A NECESSARY EXTRA?
Kim H1, Gurrin L2, Liew D1
1The University of Melbourne, Fitzroy, Victoria, Australia, 2University of Melbourne, Carlton, 
Victoria, Australia
OBJECTIVES: Probabilistic sensitivity analysis (PSA) is a useful tool to assess param-
eter uncertainty, but being among the more technically advanced methods in cost 
effectiveness modeling, it is sometimes underutilized. However, following the incor-
poration of PSA by NICE, the English HTA agency, into their guidelines in 2005, 
there was a call for the routine use of PSA in economic modeling. This study investi-
gates whether these two developments have had an effect on cost-effectiveness model-
ing practice, and also reviews current requirements for PSA in reimbursement 
guidelines globally. METHODS: The following three journals in which cost effective-
ness analyses are most often published were included in the study: Medical Decision 
Making, Pharmacoeconomics and Value in Health. All papers published in these three 
journals in 2004 and 2009 respectively were assessed. In addition, pharmacoeconomic 
guidelines from 31 countries were compared for the requirement of PSA in reimburse-
ment submissions. RESULTS: In the three journals from 2004 to 2009, the overall 
number of articles presenting cost-effectiveness modeling increased from 41 (2004) to 
55 (2009). In 2009, 69% of these articles presented PSA, compared to only 32% in 
2004. Of a total of 31 national pharmacoeconomic guidelines, 12 mention PSA. 
However, only six of these require this form of analysis to be included in reimburse-
ment submissions. Many countries with well established requirements for economic 
analysis in reimbursement submissions, such as Australia, do not require PSA. CON-
CLUSIONS: The usage of PSA to investigating parameter uncertainty is now common 
and increasing. The trend is also starting to show in the reimbursement agencies’ 
guidelines. 
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CHINESE PAYERS’ VIEW OF PHARMACEUTICAL VALUE ATTRIBUTES: 
WHICH EVIDENCE DRIVES ACCESS?
Shankland BDT
Double Helix Consulting, London, UK
OBJECTIVES: The evidence needs of payers in mainland China at the national, 
regional and local hospital level are poorly understood. As such, analysis is required 
to capture payer preferences regarding evidence submissions from pharmaceutical 
companies and identify emerging trends in value evidence needs. METHODS: A 
qualitative telephone survey of 30 key payers in Tier 3A hospitals, provincial funding 
bodies and national decision-making groups was conducted. Respondents were asked 
to score the impact of the following value attributes in their routine assessment of 
health-care products for formulary listing and/or reimbursement: 1) Innovation; 2) 
Health-related quality of life; 3) Unmet need; 4) Cost effectiveness; 5) Price; 6) Budget 
impact; 7) Safety; 8) Efﬁ cacy in head-to-head trials; and 9) Efﬁ cacy in selected popula-
tions. Scores derived were weighted according to a market impact assessment in order 
to derive maximal scores for each evidence type. RESULTS: Hospital payers reported 
that budget impact was the least signiﬁ cant evidence type (Score 5.6), due to the “self-
pay” model of patient access in China. Among hospital and provincial payers, price 
was the second least signiﬁ cant attribute (Score 6.3), due to the separation of pricing 
functions and assessment of clinical evidence in China. However, efﬁ cacy in head-to-
head studies (Score 7.5) and safety (Score 8.3) were the most desired attributes. 
CONCLUSIONS: Awareness of cost-effectiveness is at an early stage in major hospi-
tals in China; the key attributes continue to be safety and efﬁ cacy. However, there is 
a trend toward requirement of health-related quality of life data at the national payer 
level, particularly regarding oncology medicines. Further research is needed in this 
area, in order to gain a more detailed understanding from the pharmaceutical company 
perspective. 
HEALTH CARE USE & POLICY STUDIES – Health Care Research & 
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THE EVALUATION OF HEALTH-CARE SYSTEMS OF CHINA, HONG 
KONG, VIETNAM, THAILAND, MALAYSIA, SINGAPORE AND 
AUSTRALIA
Chan HYH, Steadman KJ, Hollingworth S, Nissen LM
University of Queensland, Brisbane, Australia
OBJECTIVES: To examine the health-care systems of China, Hong Kong, Vietnam, 
Thailand, Malaysia, Singapore and Australia using a pre-determined set of indicators. 
These were used to assess each system in terms of accessibility, effectiveness, efﬁ ciency, 
quality and responsiveness. METHODS: This study was a qualitative study. A set of 
indicators and sub-indicators was developed based on indicators used by the World 
Health Organisation, United Nations, the Organisation for Economic Co-operation 
Development (Health Care Quality Indicator Project), and from health frameworks 
of Australia, New Zealand, Canada, USA and UK. The indicators were used to assess 
health-care systems from an operational perspective. A literature search and interviews 
with relevant academics and government ofﬁ cials were conducted to address each 
indicator. This provided a more comprehensive view of the functioning of each health-
care system and how the system itself is regulated and provides health-care services 
to its people. RESULTS: Each of the surveyed countries have certain measures or 
programs in place to address health-care accessibility. The majority of the countries 
have clear guidelines to improve effectiveness and efﬁ ciency. However, most develop-
ing Asian countries lack clear programs to assess the quality and responsiveness of 
their health-care systems. CONCLUSIONS: Different countries have different health 
considerations and priorities in terms of politics, ﬁ nance and resources where health-
care systems are concerned. Each has its respective strengths and weaknesses. What 
is appropriate for one country may not be suitable for another. This evaluation pro-
vided clarity and insight into the operation of each system and highlighted areas that 
require further attention. Interviews with local academics, government ofﬁ cials and 
other health-care stakeholders in each country yielded a more comprehensive and 
in-depth understanding on the functioning of each health-care system. 
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HEALTH TECHNOLOGY ASSESSMENTS: INDICATORS OF 
DEVELOPMENT IN ASIA
Chowdhury CA, Martin de Bustamante M
Insight Strategy Advisors, New York City, NY, USA
OBJECTIVES: To understand the historical climate through which ten Asian markets 
arrived at the establishment of an HTA authoritative body, and the extent to which 
pharmacoeconomic evaluations have evolved in each of these markets. METHODS: 
Secondary and primary research was conducted in South Korea, Thailand, Philippines, 
Taiwan, Singapore, Malaysia, Indonesia, India, China and Japan to examine political 
and economic changes over the last 30 years. The results were compiled and analyzed 
along with other metrics, such as pricing legislation, health-care coverage, and HTA 
development to determine a correlative pattern for Asian pharmacoeconomic develop-
ment. RESULTS: While three of the studied markets are exceptions to the trend, we 
believe the other seven will follow the a discernible course of events. A change in 
political climate, desire for universal health care, ﬁ nancial crisis and strong develop-
ment of a national formulary are all policy objectives and events along the path toward 
HTA development. HTA establishment in those seven countries is at various phases 
of development, but for most of the markets creation of an HTA unit and utilization 
of it is the next step in their pharmaceutical market evolution. CONCLUSIONS: 
Developing pharmaceutical markets have become reliant on pharmacoeconomic data 
to determine the true value of innovative pharmaceutical products. The establishment 
of an HTA body in these Asian countries will continue to develop and will become 
an important aspect of their pharmaceutical market expansion, therefore the subject 
matter warrants further research and attention. 
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ANALYSIS OF THE TECHNICAL EFFICIENCY IN THREE TEACHING 
HOSPITALS IN MALAYSIA
Moshiri H, Aljunid S
UNU-IIGH, Kuala Lumpur, Malaysia
OBJECTIVES: The measurement of efﬁ ciency is usually the ﬁ rst step in auditing 
performance of hospitals. Measuring hospital efﬁ ciency provides useful information 
for hospital managers. It constitutes the rational framework for the distribution of 
human and other resources between and within hospitals. This study focuses on 
measuring and evaluating technical efﬁ ciency in teaching hospitals at department level 
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in Malaysia. METHODS: A non-parametric method called Data Envelopment Analy-
sis (DEA) with two assumptions : Variable Return to Scale (VRS) and Constant Return 
to Scale (CRS), was used to calculate and compare the efﬁ ciency scores for selected 
hospitals’ clinical departments between the year 1998 and 2006. DEA input oriented 
analysis indicates how the inefﬁ cient units could adjust their inputs to reach the efﬁ -
ciency frontier. RESULTS: Based on CRS model the mean efﬁ ciency scores in Hospital 
A departments were 76%. One department was around 50% and six departments 
were between 50% and 90% and three departments were more than 90%. The mean 
efﬁ ciency scores in Hospital B was 92%. In this hospital, two departments were 
between 75% and 90% and two departments had efﬁ ciency score equal 100% during 
study period. In Hospital C all departments were more than 75% and one department 
had efﬁ ciency score equals 100%. The results based on VRS model showed similar 
trends. CONCLUSIONS: The mean of efﬁ ciency score according different assump-
tions of Hospital B was higher than two other hospitals. The results showed that few 
departments are efﬁ cient and rests are considered inefﬁ cient and need to ﬁ nd optimum 
mixture of inputs combination. It is suggested that Hospital A and Hospital C should 
consider to improve their management of the resource inputs in inefﬁ cient department 
in order to enhance their efﬁ ciencies. 
HEALTH CARE USE & POLICY STUDIES – Health Technology Assessment 
Programs
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PRIORITIZATION OF HEALTH POLICY AND SYSTEM RESEARCH 
TOPICS IN THAILAND: MAKING IT SYSTEMATIC, TRANSPARENT AND 
PARTICIPATORY
Pilasant S, Yothasamut J, Tosagnuan K, Werayingyong P, Tantivess S, Teerawattananon Y
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand
OBJECTIVES: A growing concern is that health policy and system researches (HPSR) 
should address the needs of potential users, and subsequently have substantial impacts 
on policy decisions and professional practices. The purpose of this study is to describe 
the experience on the annual HPSR topic prioritization conducted by Thailand’s 
Health Systems Research Institute and its alliances. METHODS: Narrative descriptive 
and quantitative approaches were employed to illustrate the processes of and results 
from the HPSR topic prioritization in 2010. RESULTS: The prioritization process was 
carried out on the basis of systematicness and transparency, with participation by key 
stakeholders including policymakers, academics, health professionals, civil society, 
and industries. There was a call for research topic proposals from stakeholders in 
November and December 2009. A total of 120 topics suggested by 66 organizations 
were then prioritized by 90 representatives of stakeholder organizations. Multiple 
criteria introduced in this step involved policy relevance; disease burden; economic 
impact; social and ethical aspects; variation in practices; possibility of changing prac-
tices; and public concerns. It was found that topics related to diseases with high 
burden, relating to service delivery especially on health promotion and disease preven-
tion, and those submitted by central government agencies were more likely to get high 
priority than others. In addition, results from self-administrative survey demonstrated 
that over 92% of stakeholders strongly supported and expressed their interest to 
participate in the next annual topic prioritization process. CONCLUSIONS: This case 
study demonstrated that it is feasible to develop clear criteria and transparent process 
for prioritization of HPSR topics. Lessons learned from this case study can be useful 
for improving mechanism for selecting HPSR topics in other settings. 
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COMPLEXITY INCREASES UNCERTAINTY: THE IMPACT OF PBAC 
GUIDELINES (VERSION 4) ON PBAC DECISION-MAKING
Chollet M, Lindsay P, Gonzalo F
Sanoﬁ -Aventis Australia, Macquarie Park, Australia
OBJECTIVES: In Australia, the Pharmaceutical Beneﬁ ts Advisory Committee (PBAC) 
makes recommendations to the Minister for Health on the reimbursement of pharma-
ceuticals. The sponsor’s submission is accepted by the PBAC if the drug is determined 
to be clinically effective and also cost-effective. New PBAC Guidelines on how to 
prepare a submission (version 4) were introduced in 2008. These new Guidelines 
sought to reduce the uncertainty for the PBAC in accepting the many inferences made 
in major submissions. We assessed whether the New Guidelines have indeed reduced 
the PBAC’s uncertainty in their decision-making. METHODS: Since June 2003 all 
PBAC recommendations have been made public on the Department of Health & 
Ageing website. Public Summary Documents (PSD) are available for PBAC consider-
ations relating to the PBS listing of medicines since July 2005 meeting. We reviewed 
all the PSDs reported during the period of July 2005 to July 2009. For each PSD, we 
estimated the average number of times that the words “uncertain/uncertainties/uncer-
tainty” appear per PSD page. We compared the results for the period before and after 
the introduction of version 4 of the PBAC Guidelines. RESULTS: The average number 
of times that the words “uncertain/uncertainties/uncertainty” appeared per PSD page 
was signiﬁ cantly higher for the period after the introduction of version 4 of the PBAC 
Guidelines compared to the period before (0.51 vs. 0.66, P < 0.00001). CONCLU-
SIONS: The introduction of version 4 of the PBAC Guidelines in 2008 has led to an 
increase in the complexity and, thus, uncertainty faced by PBAC during their delibera-
tions around reimbursement of pharmaceuticals in Australia. There was a signiﬁ cant 
30% increase in the number of times that the word “uncertain/uncertainties/uncer-
tainty” was found per PSD page compared with the period prior to the introduction 
of the version 4 of the Guidelines (2003–2008). 
HEALTH CARE USE & POLICY STUDIES – Prescribing Behavior & 
Treatment Guidelines
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THE EFFECTS OF DIRECT BILLING SYSTEM IN PATIENTS WITH 
CIVIL-SERVANT MEDICAL BENEFIT SCHEMES ON PRESCRIBING 
PATTERNS
Dilokthornsakul P, Chaiyakunapruk N, Nimpitakpong P
Naresuan University, Muang, Phitsanulok, Thailand
OBJECTIVES: In 2006, the reimbursement system for civil-servant medical beneﬁ t 
schemes beneﬁ ciaries in Thailand was changed to direct billing system. It was 
unknown how this new system affects drug expenditures and the number of drug 
supply given to beneﬁ ciaries. This study aims to assess the effects of direct billing 
system on prescribing patterns. METHODS: This study was undertaken with retro-
spective cohort approach. We used the data recorded in databases of a university 
hospital in northern part of Thailand. We undertook the data on all patients with 
civil-servant medical beneﬁ t schemes who came to out-patients department between 
October 1, 2005 and March 31, 2007. Mean cost of medication, number of days’ 
supplies and medication possession ratio (MPR) of ﬁ ve highest costs of oral medication 
were calculated in 1 year before and after the system was changed. RESULTS: Out 
of 43,897 visits made at the hospital, 15,632 (36%) were under civil-servant medical 
beneﬁ t schemes. Eighty-eight percent (13,785/15,632) received medications during 
visit. The total costs of medication increased from 2 million to 4 million baths in 1 
year. Glucosamine, atorvastatin, rosiglitazone, clopidogrel and diacerin were highest 
used in terms of drug cost. Averages of day’s supplies based on these medications 
increased from 1.29 to 1.48 months per a prescription. Proportion of patients receiving 
medications more than 3 months, was slightly increased from 1.82% to 2.43%. Three 
out of ﬁ ve medications had higher MPR after system was changed (Relative risk 
ranged on 1.19–2.32). Two of these were statistical signiﬁ cant. CONCLUSIONS: The 
direct billing system affects prescribing patterns as indicated by trend of increased 
number of day’s supplies and higher medication possession ratio. Further evidence 
remains needed. Policymakers need to consider all relevant and important conse-
quences associated with the new system prior to making policy decision-making. 
INDIVIDUAL’S HEALTH – Clinical Outcomes Studies
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CRITICAL APPRAISAL OF SYSTEMATIC REVIEWS ASSESSING SAFETY 
OUTCOMES OF SSRIS IN THE PERINATAL PERIOD
Merlo GB, Elliot L, Campbell S, Norris S
Health Technology Analysts Pty Ltd, Sydney, NSW, Australia
OBJECTIVES: A systematic appraisal was conducted of published systematic reviews 
that assessed the harms associated with selective serotonergic reuptake inhibitors 
(SSRIs) in the perinatal period, both for the mother and infant. METHODS: A sys-
tematic method of literature searching and selection was employed for this review. 
Searches were conducted in EMBASE, Medline and the Cochrane Database of Sys-
tematic Reviews. Studies were eligible if they evaluated pregnancy or infant-related 
safety outcomes for SSRI use in pregnant or lactating women. RESULTS: The litera-
ture search identiﬁ ed seventeen systematic reviews and three subsequently published 
prospective cohort studies. None of the systematic reviews assessing serotonergic 
antidepressants as a group found an association with congenital malformations. An 
association between paroxetine exposure and infant cardiovascular malformations has 
been reported in the literature; however, more recent evidence from a large systematic 
review shows no relationship between paroxetine exposure and congenital cardiac 
malformations. Neonatal symptoms (such as withdrawal symptoms, lower Apgar 
score, and diminished response to pain stimulus) have been reported in 20–30% of 
infants with third trimester SSRI exposure. All of the reviews reported the symptoms 
as mild and self-limiting. Several SRs found a signiﬁ cant association between SSRI use 
in pregnancy and premature delivery, low birthweight, and admission to special care 
nurseries. There is conﬂ icting evidence regarding the long-term neurodevelopmental 
risks of serotonergic antidepressants. Although the levels of SSRIs in breast milk are 
relatively low, the evidence for the safety of antidepressant exposure via breastfeeding 
is limited. CONCLUSIONS: SSRI exposure during pregnancy is associated with 
mostly minor and temporary adverse outcomes for the newborn. The risk of these 
outcomes needs to be balanced with the risk of adverse outcomes resulting from SSRI 
withdrawal for the mother. 
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IMPACT OF HPV VACCINATION ON CERVICAL CANCER IN ASIA: 
RESULTS OF A STATIC MODEL
Demarteau N1, Van Kriekinge G2, Castellsagué X3
1GlaxoSmithKline Biologicals, Wavre, Belgium; 2GSK Bio, Wavre, Belgium; 3Institut Català 
d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain
OBJECTIVES: Estimate the potential clinical effect of HPV vaccination with a bivalent 
HPV-16/18 vaccine in Asian countries including the effect of cross-protection against 
non-vaccine oncogenic HPV types. METHODS: A static population model estimates 
